Press Release: Novartis twice-yearly* Leqvio(R) -2-

References

1. Data on file. Study NCT05763875. Novartis Pharmaceuticals Corp; 2024.

2. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the

Primary Prevention of Cardiovascular Disease. Journal of the American

College of Cardiology. 2019;74(10):e177-e232.

doi:https://doi.org/10.1016/j.jacc.2019.03.010

3. ClinicalTrials.gov. NCT05763875. Accessed August 21, 2024.

https://clinicaltrials.gov/study/NCT05763875

4. Leqvio. Summary of Product Characteristics. Novartis.

5. Leqvio. Prescribing information. Novartis Pharmaceuticals Corp.

6. National Medical Products Administration. Drug approval document delivery

information. Published August 24, 2023. Accessed March 12, 2024.

https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20230824155809182.html

7. Pharmaceutical and Medicinal Devices Agency Japan. New drugs approved in

FY 2023 document. Accessed August 21, 2024.

https://www.pmda.go.jp/files/000269225.pdf

8. American Heart Association. More than half of U.S. adults don't know

heart disease is leading cause of death, despite 100-year reign.

Published January 24, 2024. Accessed August 21, 2024.

https://newsroom.heart.org/news/more-than-half-of-u-s-adults-dont-know-heart-disease-is-leading-cause-of-death-despite-100-year-reign

9. World Heart Federation. World Heart Report. Published May 20, 2023.

Accessed August 21, 2024.

https://world-heart-federation.org/wp-content/uploads/World-Heart-Report-2023.pdf

10. World Health Organization. Cardiovascular diseases (CVDs). Published June

11, 2021. Accessed August 21, 2024.

https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-

(cvds)

11. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke

statistics--2012 update: a report from the American Heart Association.

Circulation. 2012;125(1):e2-e220.

12. Kim H, Kim S, Han S, et al. Prevalence and incidence of atherosclerotic

cardiovascular disease and its risk factors in Korea: a nationwide

population-based study. BMC Public Health. 2019;19(1):1112.

13. Grundy SM, Stone NJ, Bailey AL, et al. 2018

AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the

management of blood cholesterol: a report of the American College of

Cardiology/American Heart Association Task Force on Clinical Practice

Guidelines. Circulation. 2019;139:e1082--e1143.

14. Goldstein JL, Brown MS. A century of cholesterol and coronaries: from

plaques to genes to statins. Cell. 2015;161(1):161-172.

15. Ference BA, Graham I, Tokgozoglu L, Catapano AL. Impact of lipids on

cardiovascular health: JACC Health Promotion Series. J Am Coll Cardiol.

2018;72(10):1141-1156.

# # #

Novartis Media Relations

E-mail:media.relations@novartis.com

Central North America

Anja von Treskow +41 79 392 9697 Michael Meo +1 862 274 5414

Anna Schäfers +41 79 801 7267

Switzerland

Satoshi Sugimoto +41 79 619 2035

Novartis Investor Relations

Central investor relations line: +41 61 324 7944

E-mail:investor.relations@novartis.com

Central North America

Isabella Zinck +41 61 324 7188 Sloan Simpson +1 862 345 4440

Nicole Zinsli-Somm +41 61 324 3809 Jonathan Graham +1 201 602 9921

Imke Kappes +41 61 324 8269 Parag Mahanti +1 973 876 4912

(END) Dow Jones Newswires

August 28, 2024 01:15 ET (05:15 GMT)